Myomo (NYSEAMERICAN:MYO) Stock Breaks Below Fifty Day Moving Average - Time to Sell?

Key Points

• Myomo shares fell below their 50-day moving average of $1.38, trading as low as $1.22 and last changing hands at $1.27; the stock was down 9.3%.
• Q3 revenue rose 22.2% year over year to $12.3 million, beating expectations, while adjusted EBITDA reached breakeven. The company’s 2026 revenue guidance of $46 million–$47 million also topped consensus.
• Despite improving results, Myomo remains unprofitable, reporting a $4.2 million net loss and $1.3 million in operating cash outflow for the quarter, with $11.1 million in cash. Insiders also sold shares during the last quarter.

Myomo, Inc. (NYSEAMERICAN:MYO - Get Free Report)'s share price crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.38 and traded as low as $1.22. Myomo shares last traded at $1.27, with a volume of 498,523 shares changing hands.

More Myomo News

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Q3 revenue increased 22.2% year over year to $12.3 million, exceeding analyst expectations, while gross profit rose 36.4% to $8.8 million. The company also reported breakeven adjusted EBITDA, signaling improved operating leverage. Myomo Q3 results
• Positive Sentiment: Myomo set 2026 revenue guidance at $46 million–$47 million, above the $45.5 million consensus estimate, and expects modest sequential gross-margin improvement in Q4. Its reported Q3 loss of $0.07 per share was also narrower than the $0.08 loss analysts expected. Myomo updates revenue outlook
• Negative Sentiment: The business remains unprofitable: a third-party results summary cited a $4.2 million net loss and $1.3 million in operating cash outflow for the quarter. Myomo ended Q3 with $11.1 million in cash and $31.1 million in liabilities, keeping execution and financing needs in focus. Myomo Q3 financial summary

Myomo Stock Down 9.3%

The business has a fifty day moving average of $1.38 and a 200 day moving average of $1.09. The stock has a market cap of $50.30 million, a price-to-earnings ratio of -3.63 and a beta of 1.74. The company has a debt-to-equity ratio of 1.98, a current ratio of 2.31 and a quick ratio of 2.01.

Myomo (NYSEAMERICAN:MYO - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The firm had revenue of $12.33 million during the quarter, compared to analysts' expectations of $11.51 million. Myomo had a negative net margin of 33.14% and a negative return on equity of 152.04%. On average, equities analysts predict that Myomo, Inc. will post -0.32 earnings per share for the current year.

Insider Buying and Selling at Myomo

In other news, insider Harry Kovelman sold 17,250 shares of the firm's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total transaction of $29,842.50. Following the transaction, the insider owned 105,983 shares in the company, valued at approximately $183,350.59. This trade represents a 14.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 47,738 shares of company stock worth $70,662. 12.14% of the stock is currently owned by company insiders.

About Myomo

Myomo, Inc. is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user's residual muscle signals and assists movement of the arm and hand. The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.